PL369426A1 - Sposób leczenia - Google Patents

Sposób leczenia

Info

Publication number: PL369426A1
Authority: PL; Poland
Prior art keywords: treatment; darifenacin; urgency; medicament; manufacture
Prior art date: 2001-12-14

Application number

PL02369426A

Other languages

English (en)

Other versions

PL206034B1 (pl

Inventor

Enrico Colii

Paul Quinn

Dzelal Serdarevic

Laurence Howard Skillern

Original Assignee

Novartis International Pharmaceutical Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-14

Filing date

2002-03-05

Publication date

2005-04-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL369426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-05 Application filed by Novartis International Pharmaceutical Ltd. filed Critical Novartis International Pharmaceutical Ltd.

2005-04-18 Publication of PL369426A1 publication Critical patent/PL369426A1/pl

2010-06-30 Publication of PL206034B1 publication Critical patent/PL206034B1/pl

Links

206010020853 Hypertonic bladder Diseases 0.000 abstract 1
208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 abstract 1
229960002677 darifenacin Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
208000020629 overactive bladder Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Chemical Treatment Of Metals (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Document Processing Apparatus (AREA)
Processing Of Meat And Fish (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)
Inorganic Insulating Materials (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

PL369426A 2001-12-14 2002-03-05 Zastosowanie daryfenacyny PL206034B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0129962.7A GB0129962D0 (en)	2001-12-14	2001-12-14	Method of treatment

Publications (2)

Publication Number	Publication Date
PL369426A1 true PL369426A1 (pl)	2005-04-18
PL206034B1 PL206034B1 (pl)	2010-06-30

Family

ID=9927643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL369426A PL206034B1 (pl)	2001-12-14	2002-03-05	Zastosowanie daryfenacyny

Country Status (27)

Country	Link
US (3)	US20030130338A1 (pl)
EP (1)	EP1458376B1 (pl)
JP (3)	JP2005516925A (pl)
KR (1)	KR100889086B1 (pl)
CN (1)	CN100488505C (pl)
AT (1)	ATE341323T1 (pl)
AU (1)	AU2002236141B2 (pl)
BR (1)	BR0214925A (pl)
CA (1)	CA2469702C (pl)
CY (1)	CY1105814T1 (pl)
CZ (1)	CZ301283B6 (pl)
DE (1)	DE60215219T2 (pl)
DK (1)	DK1458376T3 (pl)
ES (1)	ES2276910T3 (pl)
GB (1)	GB0129962D0 (pl)
HU (1)	HU229908B1 (pl)
IL (2)	IL162391A0 (pl)
MX (1)	MXPA04005760A (pl)
NO (1)	NO20042586L (pl)
NZ (1)	NZ533421A (pl)
PL (1)	PL206034B1 (pl)
PT (1)	PT1458376E (pl)
RU (1)	RU2321398C2 (pl)
SI (1)	SI1458376T1 (pl)
SK (1)	SK287510B6 (pl)
WO (1)	WO2003051354A1 (pl)
ZA (1)	ZA200404289B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007109142A2 (en) *	2006-03-17	2007-09-27	Oregon Health & Science University	M3 muscarinic receptor antagonists for treating tumors
CN101084891A (zh) *	2007-06-29	2007-12-12	北京本草天源药物研究院	一种用于口服的达非那新或其药用盐的药物制剂
CZ300895B6 (cs) *	2008-01-28	2009-09-02	Zentiva, A. S.	Zpusob prípravy Darifenacinu
MY160652A (en) *	2009-02-04	2017-03-15	Astellas Pharma Inc	Pharmaceutical composition for oral administration
CN102048706B (zh) *	2011-01-12	2012-02-22	山东创新药物研发有限公司	一种氢溴酸达非那新缓释片及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8906166D0 (en) *	1989-03-17	1989-05-04	Pfizer Ltd	Therapeutic agents
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations

2001
- 2001-12-14 GB GBGB0129962.7A patent/GB0129962D0/en not_active Ceased
2002
- 2002-03-05 HU HU0402625A patent/HU229908B1/hu not_active IP Right Cessation
- 2002-03-05 EP EP02702623A patent/EP1458376B1/en not_active Expired - Lifetime
- 2002-03-05 CN CNB028249364A patent/CN100488505C/zh not_active Expired - Lifetime
- 2002-03-05 ES ES02702623T patent/ES2276910T3/es not_active Expired - Lifetime
- 2002-03-05 NZ NZ533421A patent/NZ533421A/en not_active IP Right Cessation
- 2002-03-05 WO PCT/IB2002/000664 patent/WO2003051354A1/en not_active Ceased
- 2002-03-05 MX MXPA04005760A patent/MXPA04005760A/es active IP Right Grant
- 2002-03-05 PT PT02702623T patent/PT1458376E/pt unknown
- 2002-03-05 BR BR0214925-7A patent/BR0214925A/pt active Search and Examination
- 2002-03-05 KR KR1020047009000A patent/KR100889086B1/ko not_active Expired - Lifetime
- 2002-03-05 PL PL369426A patent/PL206034B1/pl unknown
- 2002-03-05 JP JP2003552287A patent/JP2005516925A/ja not_active Withdrawn
- 2002-03-05 AT AT02702623T patent/ATE341323T1/de active
- 2002-03-05 SK SK250-2004A patent/SK287510B6/sk not_active IP Right Cessation
- 2002-03-05 DE DE60215219T patent/DE60215219T2/de not_active Expired - Lifetime
- 2002-03-05 DK DK02702623T patent/DK1458376T3/da active
- 2002-03-05 CA CA2469702A patent/CA2469702C/en not_active Expired - Lifetime
- 2002-03-05 CZ CZ20040719A patent/CZ301283B6/cs not_active IP Right Cessation
- 2002-03-05 RU RU2004121780/15A patent/RU2321398C2/ru active
- 2002-03-05 IL IL16239102A patent/IL162391A0/xx unknown
- 2002-03-05 SI SI200230464T patent/SI1458376T1/sl unknown
- 2002-03-05 AU AU2002236141A patent/AU2002236141B2/en not_active Expired
- 2002-09-26 US US10/256,420 patent/US20030130338A1/en not_active Abandoned
2004
- 2004-06-01 ZA ZA2004/04289A patent/ZA200404289B/en unknown
- 2004-06-07 IL IL162391A patent/IL162391A/en active IP Right Grant
- 2004-06-18 NO NO20042586A patent/NO20042586L/no not_active Application Discontinuation
2006
- 2006-11-30 CY CY20061101729T patent/CY1105814T1/el unknown
2007
- 2007-07-19 US US11/880,006 patent/US20070264333A1/en not_active Abandoned
2009
- 2009-03-04 US US12/397,433 patent/US8748476B2/en not_active Expired - Lifetime
- 2009-10-30 JP JP2009250519A patent/JP2010024244A/ja not_active Withdrawn
2013
- 2013-07-11 JP JP2013145736A patent/JP2013199506A/ja active Pending

Also Published As

Publication number	Publication date
NO20042586L (no)	2004-06-18
DE60215219T2 (de)	2007-10-18
KR100889086B1 (ko)	2009-03-16
SI1458376T1 (sl)	2007-06-30
JP2010024244A (ja)	2010-02-04
CZ2004719A3 (cs)	2005-01-12
AU2002236141A1 (en)	2003-06-30
US20090162433A1 (en)	2009-06-25
ES2276910T3 (es)	2007-07-01
IL162391A0 (en)	2005-11-20
GB0129962D0 (en)	2002-02-06
EP1458376B1 (en)	2006-10-04
DE60215219D1 (de)	2006-11-16
PL206034B1 (pl)	2010-06-30
JP2013199506A (ja)	2013-10-03
BR0214925A (pt)	2004-12-21
CN1604777A (zh)	2005-04-06
JP2005516925A (ja)	2005-06-09
ZA200404289B (en)	2005-09-28
CZ301283B6 (cs)	2009-12-30
ATE341323T1 (de)	2006-10-15
CN100488505C (zh)	2009-05-20
HU229908B1 (hu)	2014-12-29
DK1458376T3 (da)	2007-02-12
NZ533421A (en)	2007-02-23
SK287510B6 (sk)	2010-12-07
WO2003051354A1 (en)	2003-06-26
EP1458376A1 (en)	2004-09-22
HUP0402625A2 (hu)	2005-04-28
IL162391A (en)	2012-04-30
SK2502004A3 (en)	2004-10-05
CA2469702A1 (en)	2003-06-26
CY1105814T1 (el)	2011-02-02
US8748476B2 (en)	2014-06-10
US20030130338A1 (en)	2003-07-10
RU2004121780A (ru)	2005-08-10
KR20040066892A (ko)	2004-07-27
MXPA04005760A (es)	2005-03-31
AU2002236141B2 (en)	2007-02-01
HK1073779A1 (zh)	2005-10-21
RU2321398C2 (ru)	2008-04-10
US20070264333A1 (en)	2007-11-15
CA2469702C (en)	2010-07-06
PT1458376E (pt)	2007-01-31

Publication	Publication Date	Title
MY127290A (en)	2006-11-30	New use of flibanserin
PL1663244T3 (pl)	2008-01-31	Pochodne pterydyny do leczenia chorób związanych z TNF-alfa
EP2087892A3 (en)	2009-09-30	(S,S) reboxetine for treating age associated learning and mental disorders
YU37602A (sh)	2005-07-19	Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
YU71901A (sh)	2005-07-19	NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
WO2004043341A3 (en)	2004-07-15	Treatment for hemorrhagic shock
GB0002336D0 (en)	2000-03-22	Medicaments
GB0020504D0 (en)	2000-10-11	Therapeutic method
WO2004073615A3 (en)	2005-06-16	Deazaflavin compounds and methods of use thereof
IL143985A0 (en)	2002-04-21	New use of melagatran
EP1262197A3 (en)	2002-12-18	Combination treatment for sleep disorders including sleep apnea
BG108452A (en)	2005-02-28	Tablet comprising cetirizine and pseudoephedrine
JO3446B1 (ar)	2020-07-05	طريقة لمعالجة الأرق الأولي
GB0129962D0 (en)	2002-02-06	Method of treatment
SE9902597D0 (sv)	1999-07-06	New use
PL356001A1 (pl)	2004-05-31	Zastosowanie antagonistów receptorów beta-adrenergicznych do wytwarzania leku do leczenia zaburzeń zewnętrznej siatkówki
IL158186A0 (en)	2004-03-28	Pharmaceutically active compounds and methods of use
MXPA04001805A (es)	2004-07-08	Nueva forma de dosificacion oral de liberacion prolongada.
UA83017C2 (uk)	2008-06-10	Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
MY124089A (en)	2006-06-30	Use of cetirizine for preventing the onset of asthma
PL367628A1 (pl)	2005-03-07	Zastosowanie alkanoilo L-karnityny do sporządzenia leku mającego zastosowanie w leczenia anhedonii
AU2001276323A1 (en)	2002-02-13	Use of n-oleoylethanolamine for treating psoriasis
HRP20040165A2 (en)	2004-10-31	Citalopram for the treatment of elevated blood pressure
NZ514490A (en)	2004-01-30	Method and means for treating post-polio syndrome
IL164092A0 (en)	2005-12-18	The use of devazepide as analgesic agent